Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

C-reactive protein does not diagnose nonalcoholic steatohepatitis

C-reactive protein is increased in both liver and adipose tissue in obese patients independently from non-alcoholic steatohepatitis, report doctors in this month's American Journal of Gastroenterology.

News image

fiogf49gjkf04

C-reactive protein is a nonspecific marker of inflammation that is moderately elevated in obesity, metabolic, and type 2 diabetes.

It has been proposed as a surrogate marker of nonalcoholic steatohepatitis.

Dr Rodolphe Anty and colleagues from France evaluated its clinical usefulness in the diagnosis of nonalcoholic steatohepatitis in severely obese patients.

The patients were without or withmetabolic syndrome, diabetes, and nonalcoholic steatohepatitis.

The team of doctors characterized the potential roles of the liver and of the adipose tissue in C-reactive protein production.

The team studied 13 severely obese patients without nonalcoholic steatohepatitis and without metabolic syndrome, and 11 with with metabolic syndrome.

The doctors studied a further 7 with metabolic syndrome and diabetes and 15 with nonalcoholic steatohepatitis.

Of those with non-alcoholic steatohepatitis, 8 were without and 7 with metabolic syndrome.

For each patient, the team collected liver and adipose tissue biopsies during a bariatric surgery and were used to determine the C-reactive protein gene expression.

C-reactive protein mRNA levels were positively correlated with those of interleukin-6
American Journal of Gastroenterology

The role of interleukin-6 and lipopolysaccharide in C-reactive protein expression was also evaluated in subcutaneous adipose tissue obtained during cosmetic abdominoplasty.

The doctors elevated plasma C-reactive protein levels in severely obese patients independently of metabolic syndrome, diabetes, or nonalcoholic steatohepatitis.

The team found that C-reactive protein gene expression was not only increased in livers but also in adipose tissues of obese patients compared with controls subjects.

In human adipose tissue, C-reactive protein mRNA levels were positively correlated with those of interleukin-6.

The team observed that the C-reactive protein expression was enhanced in vitro by interleukin-6 and lipopolysaccharide.

Dr Anty's team concluded, “Plasma C-reactive protein levels are not predictive of the diagnosis of nonalcoholic steatohepatitis in severely obese patients.”

“The liver as well as the adipose tissue can produce C-reactive protein, a process which could be dependent on interleukin-6.”

“Therefore, both tissues might contribute to the elevated plasma C-reactive protein levels found in obesity.”

“In addition, the large amount of body fat may well produce an important part of the circulating C-reactive protein, further limiting its clinical usefulness in the evaluation of nonalcoholic steatohepatitis in severely obese patients.”

Am J Gastroenterol 2006: 101(8): 1824
15 August 2006

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us